International Pharmaceutical and Nutrition Expert Dr. Jean Zetlaoui Joins VALBIOTIS’ Supervisory Board
September 20 2017 - 1:30AM
Business Wire
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME
eligible), a company that specializes in developing innovative
nutrition solutions designed to prevent cardiometabolic diseases
and provide nutritional support for patients, today announced the
arrival1 of Jean Zetlaoui on Valbiotis’ Supervisory Board1.
“We look forward to welcoming Jean Zetlaoui on our Supervisory
Board. He is a man of action and a recognized pharmaceutical and
nutrition expert. He will be a strong addition to an already highly
qualified team of internationally recognized experts, and his
considerable experience in these key complementary areas for
VALBIOTIS will be a great advantage for our company’s development.
VALBIOTIS does business with major pharmaceutical and nutrition
corporations which gives us a unique, high-added-value positioning.
Zetlaoui’s arrival will further reinforce this positioning,” said
VALBIOTIS CEO Sébastien Peltier.
Existing members of the VALBIOTIS Supervisory Board include:
- Mr. Laurent Levy (PhD), Chairman of
VALBIOTIS’ Supervisory Board and Chairman of the Board of Directors
of NANOBIOTIX (ISIN code FR0011341205);
- Mr. Sébastien Bessy, Member of
VALBIOTIS’ Supervisory Board and Vice-President Global Marketing
& Portfolio Strategy of IPSEN Global PCBU;
- Mr. Philippe Vuagnat (PhD), Member of
VALBIOTIS’ Supervisory Board and CEO of SOFIMAC Partners.
“VALBIOTIS has a unique ‘Nutrition Healthcare’ positioning. By
developing preventive solutions and providing nutritional support
for cardiometabolic diseases, VALBIOTIS is delivering a strong
message, in particular by tackling pre-diabetes which affects some
130 million people in the European and American markets alone. I am
convinced that the company has everything it takes to become a
world reference and I look forward to contributing to its business
development,” said Dr. Jean Zetlaoui.
Jean Zetlaoui has over 25 years’ experience in various
managerial posts abroad and is bringing his advanced knowledge of
the pharmaceutical and nutrition sectors, of their environments and
their challenges.
He has been Scientific Director of NOVARTIS Pharma SAS since
January 2014, is a member of the Executive Committee and was also
Chief Medical Officer and member of the Nestlé Health Science
Executive Committee in Vevey, Switzerland, for 2 years,
contributing to the growth of personalized medicine and health
nutrition related business. Over the past 20 or so years, Zetlaoui
has also held various managerial and R&D positions at SANOFI,
including those of Vice-President Head of Market Access,
Vice-President Head of Global Regulatory Affairs and Vice-President
Deputy Head of Global Medical Affairs.
Jean Zetlaoui is also Vice-President of the Alliance for
Research and Innovation in Health Industries (ARIIS) and Chairman
of the working group on the attractiveness of France for clinical
research headed by Leem, an association of French pharmaceutical
companies.
Before joining the pharmaceutical industry, Dr. Jean Zetlaoui
worked as a hospital practitioner at Bicêtre CHU.
Zetlaoui holds a medical degree and a specialization in
anesthesia and resuscitation. He has also completed an Executive
MBA in Finance and International Business at the ESSEC Business
School (1991).
ABOUT VALBIOTIS
VALBIOTIS specializes in developing innovative nutrition
solutions designed to prevent cardiometabolic diseases and provide
nutritional support for patients. Its products are made for
manufacturers in the agro-food and pharmaceutical industries.
VALBIOTIS particularly focuses on solutions to prevent type 2
diabetes, NASH (nonalcoholic steatohepatitis), obesity and
cardiovascular diseases.
Valbiotis was founded in La Rochelle in early 2014 and has
formed numerous partnerships with top academic centers in France
and abroad, including the La Rochelle University, the CNRS and the
Clermont Auvergne University located in Clermont-Ferrand, where the
company opened a second office. These partnerships have enabled
Valbiotis to benefit from strong financial leverage, particularly
thanks to experts and technical partners who support its projects.
Valbiotis is a member of the “BPI Excellence” network and received
the “Innovative Company” status accorded by BPI France. Valbiotis
has also been awarded “Young Innovative Company” status and has
received major financial support from the European Union for its
research programs by obtaining support from the European Regional
Development Fund (ERDF).
Find out more about
VALBIOTIS:http://valbiotis.com/
Name: ValbiotisISIN code: FR0013254851Mnemonic code:
ALVAL
1 The appointment of Dr. Zetlaoui will be put forward at the
Annual General Meeting to be held October 26th, 2017, at 2 pm on
the 6th floor of the offices of the law firm Granrut, 91 rue du
Faubourg Saint-Honoré, 75008 Paris.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170919006229/en/
FINANCIAL COMMUNICATIONACTIFINStéphane RUIZ, +33 1 56 88
11 14sruiz@actifin.frorPRESS RELATIONSALIZE PRCaroline
Carmagnol / Wendy Rigal, +33 1 44 54 36 66valbiotis@alizerp.com
Valbiotis (EU:ALVAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valbiotis (EU:ALVAL)
Historical Stock Chart
From May 2023 to May 2024